1st Dec 2005 16:00
Stock Exchange Announcement1 December 2005Shire plc (the "Company")The Company announces that on 1 December 2005 it was notified of theacquisition in London, on that day, of ordinary shares in the Company by aDirector, and an acquisition by a Person Discharging ManagerialResponsibilities, following exercises of options held under the Shire plcSharesave Scheme. The exercise price was ‚£5.02.Notification of the acquisition of shares by a Director1,882 ordinary shares of 5p each in the Company were acquired by Mr AngusRussell, Chief Financial Officer, being 0.0004% of the issued shares of thatclass. As a result of this transaction, Mr Russell has a total interest of1,882 ordinary shares in the Company.Notification of the acquisition of shares by a Person Discharging ManagerialResponsibilities1882 ordinary shares of 5p each in the Company were acquired by Ms Tatjana May,General Counsel, Company Secretary and Executive Vice President Global LegalAffairs, being 0.0004% of the issued shares of that class. As a result of thistransaction, Ms May has a total interest of 2,606 ordinary shares in theCompany being 0.0005% of the issued shares of that class.T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 SHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on central nervous system, gastrointestinal, generalproducts and human genetic therapies - all being areas in which Shire has acommercial presence. The structure is sufficiently flexible to allow Shire totarget new therapeutic areas to the extent opportunities arise throughacquisitions. Shire believes that a carefully selected portfolio of productswith strategically aligned and relatively small-scale sales forces will deliverstrong results. Shire's strategy is to develop and market products forspecialty physicians. Shire's in-licensing and merger and acquisition effortsare focused on products in niche markets with strong intellectual propertyprotection either in the US or Europe.For further information on Shire, please visit the Company's website:www.shire.comHampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release ENDShire Pharmaceuticals Group PLCRelated Shares:
Shire